US equities |
NVDA $239.75 ▲+2.48% SPCX $169.66 ▲+6.73% MU $1,060.23 ▼-1.36% TSLA $380.93 ▲+2.79% SNDK $1,693.31 ▼-1.55% MSFT $528.69 ▲+2.16% INTC $116.45 ▼-2.41% META $743.71 ▲+2.15%
FinancialContent

Supernus Pharmaceuticals, Inc. - Common Stock (NQ:SUPN)

43.02 +0.64 (+1.51%)
Delayed Quote Updated: 3:18 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Supernus Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug ↗
Piper Sandler downgrades Supernus Pharmaceuticals due to slower-than-expected growth in Qelbree prescriptions during back-to-school season, with a revised peak sales target of $400 million. 
Via Benzinga
News headline image
This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday ↗
 
Via Benzinga
News headline image
Domino's Pizza To $510? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Announces Second Quarter 2024 Financial Results
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
For those who appreciate value investing, NASDAQ:SUPN is a compelling option with its solid fundamentals. ↗
In a market where value is scarce, SUPERNUS PHARMACEUTICALS INC (NASDAQ:SUPN) offers a refreshing opportunity with its solid fundamentals. 
Via Chartmill
News headline image
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
If You Can Only Buy One Biotech Stock in July, It Better Be One of These 3 Names ↗
Evaluating and making money from biotech stocks is incredibly difficult. These three ideas should help your quest if buying in July. 
Via InvestorPlace
News headline image
NASDAQ:SUPN is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗
SUPERNUS PHARMACEUTICALS INC (NASDAQ:SUPN) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
News headline image
Trading SMID Biotech Stocks In A Volatile Market ↗
Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a... 
Via Talk Markets
News headline image
Investors should take notice of NASDAQ:SUPN—it offers a great deal for the fundamentals it presents. ↗
SUPERNUS PHARMACEUTICALS INC (NASDAQ:SUPN) stands out as a stock that provides good value for the fundamentals it showcases. 
Via Chartmill
News headline image
Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
SUPN Stock Earnings: Supernus Pharmaceuticals Misses Revenue for Q1 2024 ↗
SUPN stock results show that Supernus Pharmaceuticals missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Supernus Announces First Quarter 2024 Financial Results
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
The Law Offices of Frank R. Cruz Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Pharmaceuticals Faces Second FDA Rejection For Investigational Device For Parkinson's Disease ↗
Supernus Pharmaceuticals receives FDA Complete Response Letter for SPN-830, an investigational apomorphine infusion device for Parkinson's disease. CRL indicates additional review needed for product... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Supernus Provides Regulatory Update for SPN-830
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >